Site
Search results (Showing 1 - 10 of 22 results)
-
References | 8 Aug 2016
Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
-
References | 13 Sep 2012
Excitability decreasing central motor plasticity is retained in multiple sclerosis patients.
Zeller D, Dang S-Y, Weise D, Rieckmann P, Toyka KV, Classen JBMC Neurol. 2012 Sep 13; 12(1):92. Epub 2012 Sep 13. PMID: 22974055. Abstract -
References | 17 Mar 2013
Multiple sclerosis in the Arabian Gulf countries: a consensus statement.
Bohlega S, Inshasi J, Al Tahan A R, Madani A B, Qahtani H, Rieckmann PJ Neurol. 2013 Mar 17. Epub 2013 Mar 17. PMID: 23504049. Abstract -
References | 21 May 2013
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Editors' PickKhan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, for the GALA Study GroupAnn Neurol. 2013 May 20. PMID: 23686821. Abstract -
References | 10 Aug 2016
Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study.
Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov RMult Scler. 2016 Aug 8. PMID: 27503905. Abstract -
References | 12 Mar 2015
ATON: Results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
Sergott RC, Bennett JL, Rieckmann P, Montalban X, Mikol D, Freudensprung U, Plitz T, van Beek J, ATON Trial GroupJ Neurol Sci. 2015 Feb 17. PMID: 25758472. Abstract -
References | 20 Jan 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Chang P, Hamlett A, Musch B, et al.N Engl J Med. 2010 Feb 4; 362(5):416-26. Epub 2010 Jan 20. PMID: 20089960. Abstract -
References | 1 Sep 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering Group.
Rieckmann P, Boyko A, Centonze D, Coles A, Elovaara I, Havrdová E, Hommes O, Lelorier J, Morrow SA, Oreja-Guevara C, et al.J Neurol. 2012 Aug 31. PMID: 22936203. Abstract -
References | 21 Dec 2012
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJJ Neurol. 2012 Dec 21. Epub 2012 Dec 21. PMID: 23263473. Abstract -
References | 15 Mar 2011
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen P S, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY Study GroupLancet Neurol. 2011 Apr; 10(4):329-37. PMID: 21397565. Abstract